B. Metzler seel. Sohn & Co. AG Makes New Investment in West Pharmaceutical Services, Inc. $WST

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 3,346 shares of West Pharmaceutical Services in the second quarter, valued at approximately $1.2 million. Several other institutional investors also initiated positions, and institutions collectively own 93.9% of the company.
• West Pharmaceutical Services reported quarterly EPS of $2.37, exceeding estimates of $2.08, while revenue rose 13.8% year over year to $872.3 million. The company forecasts full-year 2026 EPS of $8.85–$9.05.
• The company paid a quarterly dividend of $0.22 per share, equivalent to an annualized yield of about 0.2%. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $368.08.

B. Metzler seel. Sohn & Co. AG bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,346 shares of the medical instruments supplier's stock, valued at approximately $1,201,000.

Other hedge funds have also recently modified their holdings of the company. NFJ Investment Group LLC acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth about $7,759,000. Advisors Capital Management LLC acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $1,533,000. PCM Encore LLC purchased a new position in West Pharmaceutical Services during the 2nd quarter worth approximately $221,000. Vise Technologies Inc. purchased a new position in West Pharmaceutical Services during the 2nd quarter worth approximately $499,000. Finally, E Fund Management Co. Ltd. acquired a new position in West Pharmaceutical Services during the second quarter worth approximately $418,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 0.0%

Shares of WST stock opened at $352.94 on Monday. The company has a market capitalization of $24.84 billion, a P/E ratio of 45.19, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The business's 50 day moving average is $348.61 and its two-hundred day moving average is $300.19. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million during the quarter, compared to analysts' expectations of $839.98 million. During the same quarter in the prior year, the business earned $1.84 earnings per share. The company's quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services's dividend payout ratio is presently 11.27%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. BNP Paribas Exane started coverage on West Pharmaceutical Services in a research note on Monday, July 13th. They issued an "outperform" rating and a $447.00 price objective for the company. Weiss Ratings upgraded shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, August 7th. Barclays raised shares of West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. TD Cowen reiterated a "buy" rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Finally, Morgan Stanley increased their price target on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of "Moderate Buy" and a consensus target price of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source